Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.
Metacrine, Inc. will halt its non-alcoholic steatohepatitis (NASH) research and development after unveiling mixed Phase IIa data for FXR agonist MET642 in NASH patients. Now, the San Diego firm says it will move the same compound into inflammatory bowel disease (IBD), with a Phase II study in ulcerative colitis expected to begin during the first half of 2022.
This major and seemingly sudden switch in therapeutic focus for Metacrine led analysts to lower their valuations for the biotech...
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
